Background: Increasing evidence revealed that high expression level of lncRNA SNHG1 was associated with the unfavorable prognosis of cancer and maybe used as a valuable biomarker for cancer patients. The present meta>analysis is to analyze existing data to reveal potential clinical application of SNHG1 on cancer prognosis and tumor progression. All of the included studies were collected through a variety of retrieval strategies. And the articles were qualified by MOOSE and PRISMA checklists. Methods: Up to Mar 20, 2018, literature collection was performed by comprehensive search through electronic databases, including the Cochrane library, PubMed, Embase, Web of science, Springer, Science direct, and three Chinese databases: CNKI, Weipu, and Wanfang. We analyzed 14 studies that met the criteria, and concluded that the increased SHNG1 level was correlated with poor OS and tumor progression. Results: The combined results indicated that elevated SNHG1 expression level was significantly associated with poor OS (HR = 2.06, 95% CI: 1.69-2.52, P < 0.01) and PFS (HR = 2.78, 95% CI: 1.69-4.55, P < 0.01) in various cancers. Moreover, the promoted SNHG1 expression was also associated with tumor progression ((III/IV vs. I/II: HR = 1.89, 95% CI: 1.53-2.34, P < 0.01). In stratified analyses, a significantly unfavorable association of elevated lncRNA SNHG1 and OS was observed in both digestive system (HR = 2.04, 95% CI: 1.56-2.68, P < 0.01) and non-digestive system (HR = 2.09, 95% CI: 1.55-2.83, P < 0.01) cancer patients.
Background
Cancer has gradually becoming a major threaten for human health in the worldwide [1, 2] . Even though tremendous improvements had been made in cancer treatment, the long-term survival rate still remains unsatisfied in various types of cancers. The molecular mechanism underlying oncogenesis and tumor progression is still not fully elucidated, which restrict the prognostic prediction of cancer patients. Thus, it is urgent for us to identify new effective biomarkers for early diagnosis, prognosis prediction and ideal therapeutic target for cancer patients.
As a class of endogenous non coding RNA, long noncoding RNA (lncRNA) has a broad range of molecular and cellular functions, including chromatin modification, gene imprinting, alternative splicing, dosage compensation, nuclear-cytoplasmic trafficking, and inactivation of major tumor suppressor genes etc. [3] [4] [5] . Accumulating evidences of dysregulated lncRNAs in various cancers suggested that these greater than 200 nucleotides RNAs may contribute to cancer development and progression [6, 7] . Moreover, dramatic findings had suggested that lncRNAs may participate in a wide range of biological pathways which underlying oncogenesis [8] . Therefore, lncRNAs have attracted considerable attention as a mighty class of modulators and maybe serve as a potential biomarker for cancer patients [9] [10] [11] [12] .
LncRNA-SNHG1 (small nucleolar RNA host gene 1), located in 11q12.3, is expressed in broad ranges of cancer tissues [13] [14] [15] [16] . Recently, emerging evidence from fundamental and clinical studies revealed that lncRNA-SNHG1 participates in tumorigenesis and exhibits poor prognostic value in different types of cancers. However, most studies reported the prognostic value of SNHG1 in cancer patients was limited by small sample size [15, 17] . Therefore, we conducted the present quantitative metaanalysis to investigate the prognostic value of SNHG1 in various cancers.
Methods

Literature search
Articles published in English and Chinese which related to the prognostic value of lncRNA SNHG1 and tumor progression were eligible for the current analysis. Up to March 20, 2018, a comprehensive search was conducted in several electronic databases: PubMed, Web of Science, Embase, ISI Web of Knowledge, Cochrane Library, BioMed Central, Springer, ScienceDirect, together with three Chinese databases: CNKI, Weipu and Wanfang. Following keywords for the online search in these databases were included: ("long noncoding RNA-" OR "noncoding RNA-" OR "lnc RNA-" OR "small nucleolar RNA host gene 1" OR "SNHG1") AND ("carcinoma" OR "cancer" OR "tumor" OR "neoplasm") AND ("prognosis" OR "prognostic"). The reference lists of primary publications were also manually searched to achieve potential eligible studies.
Inclusion and exclusion criteria
The following selection criteria for the eligible studies were used: 1) Definite diagnosis or histopathology confirmed for cancer patients; 2) Studies investigating the prognostic features of lncRNA SNHG1 in any malignant patients; 3) Enough information for the computation of pooled hazard ratios (HR) and 95% confidence intervals (CI). Exclusion criteria for the articles included: Studies absence of prognostic outcomes; 2) Duplicated publications; 3) Non-human research, correspondences, case reports, letters, review articles and other studies without original data.
Data extraction and quality assessment
Two authors (BZD and CZZ) carefully reviewed the information such as titles, abstracts, full texts and reference lists of each eligible article independently. The enrolled literatures were then qualified by MOOSE and PRISMA checklists (Additional file 1: Table S1 and Additional file 2: Table S2 ) [18] . In case that the eligible literatures only provide the data as Kaplan-Meier survival curves, the Enguage Digitizer (Version 4.1) software was used to extract the survival information from the graphical plots as the previously described method [19] [20] [21] . Extracted items were discussed and any contradiction was arbitrated by a third investigator (YYZ) to reach a consensus. Furthermore, the necessary elements from the enrolled articles were extracted: first author's name; publication year; cancer resources; tumor type and stage; total cases; follow-up period; lncRNA SNHG1 detection method; cut-off values; HRs and corresponding 95% CIs.
Statistical analysis
The present meta analysis was performed with Stata SE 12.0 (Stata Corporation) and RevMan 5.3 software. The main statistical index, HRs and 95% CIs, was calculated for the aggregation of patient survival and tumor progression results. The heterogeneity between studies was determined by I 2 statistics. The fixed effect model was conducted in the studies with no obvious heterogeneity (I 2 < 50%) [21] [22] [23] . Potential publication bias was evaluated by performing Begg's bias test and funnel plot. P value less than 0.05 was considered as statistically significant.
Results
Eligible studies
After preliminary online search, 363 literatures in total were originally retrieved from electronic databases. After duplicates removed, 350 potential articles were then subjected to abstract screened. These 278 researches which related to the lncRNA SNHG1 expression and cancer prognosis were then excluded because they do not match the inclusion criteria. Through carefully full texts assessed the remaining 72 articles, another 58 literatures were then removed according to the exclusion criteria. Ultimately, fourteen articles were enrolled in this present study. The literature screening processes were presented as a flow diagram [14] [15] [16] [17] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] (Fig. 1) .
Study characteristics
The main features of the enrolled 14 eligible studies included a total of 1397 participants were summarized in Table 1 . Briefly, qRT-PCR was used to detect lncRNA SNHG1 expression level in all of the research studies. The detected cancer tissue samples came from neuroblastoma, esophageal squamous cell cancer, hepatocellular carcinoma, gastric cancer, epithelial ovarian cancer, osteosarcoma, lung squamous cell carcinoma, colorectal cancer, non-small cell lung cancer and lung cancer. Notably, median was selected as cutoff value in different studies. Eight of the fourteen articles focused on the association of SNHG1 with OS, PFS, EFS or RFS, and two articles investigated both OS and PFS. Figure 2 presented the forest plot result about lncRNA SNHG1 and patient outcomes. A fix-effect model was utilized to calculate the pooled effect size because no significant heterogeneity was observed among these enrolled 10 studies (I 2 = 0%). The combined results indicated that the elevated SNHG1 expression level was significantly predicted poor OS (HR = 2.06, 95% CI: 1.69-2.52, P < 0.01) and PFS (HR = 2.78, 95% CI: 1.69-4.55, P < 0.01) in various cancers. Moreover, the promoted SNHG1 level was also associated with tumor progression ((III/IV vs. I/II: HR = 1.89, 95% CI: 1.53-2.34, P < 0.01) and (III vs. I/II: HR = 1.88, 95% CI: 1.33-2.66, P < 0.01)) (Fig. 3) .
Meta-analysis
Stratified analysis
Afterwards we set out to throw light upon the prognostic effect of SNHG1 on different cancer resources. The results from stratified analysis turned out that enforced SNHG1 expression was predictive of worse outcome in digestive system (HR = 2.04, 95% CI: 1.56-2.68, P < 0.01) and non-digestive system (HR = 2.09, 95% CI: 1.55-2.83, P < 0.01) cancer patients (Fig. 2c) . No significant heterogeneity was found in the subgroup analysis.
Publication bias
To evaluate publication bias in the current meta-analysis, the indicated studies were conducted with Begg's bias test and funnel plot analysis. The result of Begg's test revealed the absence of significant publication bias (P = 0.474). The shape of the funnel plot was also symmetrically inverted funnels (Fig. 4) .
Sensitivity analysis
Through sensitivity analysis, it was uncovered that the pooled SNHG1 HR was not significantly affected by the exclusion of any single study (Fig. 5 ).
Discussion
Along with the rapid expanding of high throughput genome sequencing technologies, lncRNAs were demonstrated as novel biomarkers to more precisely evaluate the prognosis of various tumors. Recently, mounting evidence suggested that over-expression lncRNA SNHG1 correlated with poor prognosis and progression of cancer patients. However, most studies reported the prognostic value of SNHG1 expression level was limited by small sample size. To the best of our knowledge, there is no systematic meta analysis concerning about lncRNA SNHG1 expression level and cancer patient outcomes.
LncRNA SNHG1, a novel lncRNA located in 11q12.3 region and containing 11 exons, which had been found significantly up-regulated in several types of cancers. The molecular mechanisms prone to be participated in the oncogenesis and progression had gradually been unveiled. For example, the dysregulation of LncRNA SNHG1 has been demonstrated to participate in Notch and Wnt/β-catenin signaling pathways in osteosarcoma and colorectal cancer [25, 34] . LncRNA SNHG1 was also suggested to interact with DNMT1, P53 and TAP63 in GC, HC and LSCC respectively [14, 15, 28] . Moreover, lncRNA SNHG1 may conduct as a competing endogenous RNA (ceRNA) that exacerbated cancer development. Up-regulated lncRNA SNHG1 reduces the miRNAs expression level, such as miR-101-3p, miR-145, miR-195, miR-326 and miR-577 in nucleus pulposus cell proliferation, osteosarcoma, hepatocellular carcinoma, non-small cell lung cancer and nasopharyngeal carcinoma respectively [17, 26, 30, 35, 36] . These encouraged evidences urged us investigating the relationship between lncRNA SNHG1 and cancer prognosis, and our analysis firstly demonstrated that high expression level of lncRNA SNHG1 was an unfavorable predictor for the clinical outcomes of various cancer patients.
Fourteen online searched studies including 1397 patients in total were pooled in this analysis, which was considered as powerful enough to consolidate our results. Several kinds of tumors, such as neuroblastoma, esophageal squamous cell cancer, hepatocellular carcinoma, gastric cancer, epithelial ovarian cancer, osteosarcoma, lung squamous cell carcinoma, colorectal cancer, non-small cell lung cancer and lung cancer, were implemented in our study. The analysis showed a pooled HR was 2.06 (95% CI: 1.69-2.52, P < 0.01), 2.78 (95% CI: 1.69-4.55, P < 0.01) and 1.89 (95% CI: 1.53-2.34, P < 0.01) for OS, PFS and tumor progression respectively. We also demonstrated that enforced SNHG1 expression was a predictor of worse outcome in digestive system (HR = 2.04, 95% CI: 1.56-2.68, P < 0.01) and non-digestive system (HR = 2.09, 95% CI: 1.55-2.83, P < 0.01) cancer patients.
Nevertheless, limitations should be refined when interpreted lncRNA SNHG1 expression level for cancer outcomes. To start with, although no publication bias was detected by statistical methods, potential bias might exist. Articles with ideal results might be published easily, which might lead to the lack of statistical power. Furthermore, the ethnicity of the cancer patients was Asian and our results may best elucidate the correlation of lncRNA SNHG1 with Asian patients.
In summary, despite some limitations mentioned above, our meta-analysis indicated that the elevated lncRNA SNHG1 level is significantly associated with cancer patients'outcome. To strengthen our results, well-designed clinical studies and multi-ethnics clinical researches should be carried out before lncRNA SNHG1 could be applied as a prognostic marker in the routine clinical guidance of cancer patients.
Conclusions
In conclusion, the present results suggest that promoted lncRNA SNHG1 expression levels are associated with OS and lncRNA SNHG1 may be used as a prognostic marker for cancer patients. 
